Omeros Corp (OMER) Stock Price, Quote & News

Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 676 5000

Website: www.omeros.com

Address:

The Omeros Building, 201 Elliott Avenue West, Seattle, United States

LiquidThetaLEAPS Oct. 7 at 10:27 AM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $OMER Current Share Price: $4.63 Contracts: $OMER December 18, 2026 $5 Calls Scale in: $2.54- $3.11 Scale out: $3.96-$5.09 Can Easily Capture: 60% ROI Blended DTE: 438 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

uptech Oct. 7 at 12:11 AM

$OMER Last month the large Sept exp options folks lost their collective ass. But they are back for more! And OI puts are sleepy. Interesting! I think we know Sept was a reach...but October?? Could be interesting. Safe bet is Nov IMO. But I am not in that game. I loaded up on more common and re-stocked on popcorn from Costco. Game-on folks. Omeros is playing October baseball. Good luck . I hope the options players make a killing because if they do, I do. And most of you as well. Andiamo.

2 · Reply

uptech Oct. 7 at 12:00 AM

$OMER OK Frog Soup is heating up. Last large buy tranche was at 3, but I did add more for kicks in low 4s. Rally hats on folks. Lets do this. Andiamo.

0 · Reply

HarveySpecter20 Oct. 6 at 9:16 PM

$OMER

0 · Reply

albert88 Oct. 6 at 7:08 PM

$OMER 5 coming.

0 · Reply

signaljumper Oct. 6 at 4:54 PM

$OMER time to load thiss biotech stock. Infos follow soon

1 · Reply

TheNewAxe Oct. 6 at 3:33 PM

$OMER Bought my last batch at 4.67, now back to 75k shares with a cost basis under 4 bucks in my taxable accounts.

3 · Reply

Phase3 Oct. 6 at 2:42 PM

$OMER yep, she's trying to break out...

1 · Reply

MikeLogan Oct. 6 at 2:29 PM

$OMER Looks like she wants higher. I was expecting a Monday morning selloff, not decent volume and green.

1 · Reply

robertward Oct. 6 at 12:27 AM

$OMER Got a good feeling about this week! Yep, I’m gonna keep saying this every single Sunday until something good happens 🤣🤣

3 · Reply

Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program

Aug 19, 2025, 4:41 PM EDT - 6 weeks ago

Omeros Corporation (OMER) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 4:02 PM EDT - 7 weeks ago

Omeros Corporation Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 4:02 PM EDT - 2 months ago

Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025

Jul 25, 2025, 8:00 AM EDT - 2 months ago

Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering

Jun 27, 2025, 8:30 AM EDT - 3 months ago

Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA

Jun 24, 2025, 8:30 AM EDT - 3 months ago

Omeros Announces Webcast Details for Annual Meeting of Shareholders

Jun 10, 2025, 12:53 PM EDT - 4 months ago

Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision

May 27, 2025, 11:12 PM EDT - 4 months ago

Omeros: On The Brink As It Awaits Its Fall PDUFA For A Potential Blockbuster

May 27, 2025, 7:20 AM EDT - 4 months ago

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter

AGL ANIP

May 15, 2025, 9:07 PM EDT - 5 months ago

Omeros Corporation (OMER) Q1 2025 Earnings Conference Call Transcript

May 15, 2025, 4:05 PM EDT - 5 months ago

Omeros Corporation Reports First Quarter 2025 Financial Results

May 12, 2025, 5:05 PM EDT - 5 months ago

Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025

May 12, 2025, 10:35 AM EDT - 5 months ago

Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026

May 6, 2025, 9:16 AM EDT - 5 months ago

FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date

Apr 11, 2025, 3:06 PM EDT - 6 months ago

Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight

Apr 10, 2025, 9:10 AM EDT - 6 months ago

Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program

Apr 8, 2025, 9:00 AM EDT - 6 months ago

Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases

Mar 31, 2025, 8:57 PM EDT - 6 months ago

Omeros Corporation (OMER) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 4:02 PM EDT - 6 months ago

Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results

Mar 28, 2025, 7:39 AM EDT - 6 months ago

Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings

Mar 26, 2025, 9:15 AM EDT - 6 months ago

Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025

Mar 21, 2025, 9:15 AM EDT - 7 months ago

Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

Feb 24, 2025, 4:44 PM EST - 8 months ago

Omeros Corporation: Scientifically Compelling Again, But The Delay Has Cost Us

Feb 20, 2025, 9:10 AM EST - 8 months ago

Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA

Feb 14, 2025, 9:00 AM EST - 8 months ago

Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings

Feb 10, 2025, 9:00 AM EST - 8 months ago

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

Jan 16, 2025, 9:15 AM EST - 9 months ago

Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint

Dec 19, 2024, 12:28 PM EST - 10 months ago

Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges

Dec 19, 2024, 9:15 AM EST - 10 months ago

Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

Dec 10, 2024, 8:45 AM EST - 10 months ago

Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting

Dec 2, 2024, 8:45 AM EST - 11 months ago

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

Nov 21, 2024, 9:15 AM EST - 11 months ago

Omeros Corporation Provides Update on Progress Toward BLA Resubmission

Nov 13, 2024, 10:22 PM EST - 11 months ago

Omeros Corporation (OMER) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 4:02 PM EST - 11 months ago

Omeros Corporation Reports Third Quarter 2024 Financial Results

Nov 11, 2024, 4:11 PM EST - 11 months ago

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024

Oct 24, 2024, 8:45 AM EDT - 1 year ago

FDA Grants Rare Pediatric Disease Designation to Omeros' MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy

Aug 10, 2024, 1:05 AM EDT - 1 year ago

Omeros Corporation (OMER) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:02 PM EDT - 1 year ago

Omeros Corporation Reports Second Quarter 2024 Financial Results

Aug 5, 2024, 4:02 PM EDT - 1 year ago

Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024

Jun 3, 2024, 9:00 AM EDT - 1 year ago

Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028

May 15, 2024, 7:23 PM EDT - 1 year ago

Omeros Corporation (OMER) Q1 2024 Earnings Call Transcript

May 15, 2024, 4:02 PM EDT - 1 year ago

Omeros Corporation Reports First Quarter 2024 Financial Results

May 10, 2024, 8:50 AM EDT - 1 year ago

Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024

May 9, 2024, 8:50 AM EDT - 1 year ago

Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress

Apr 1, 2024, 8:09 PM EDT - 1 year ago

Omeros Corporation (OMER) Q4 2023 Earnings Call Transcript

Apr 1, 2024, 4:02 PM EDT - 1 year ago

Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results

Mar 27, 2024, 8:30 AM EDT - 1 year ago

Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024

Feb 20, 2024, 9:00 AM EST - 1 year ago

Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy

Feb 1, 2024, 9:11 AM EST - 1 year ago

Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust

LiquidThetaLEAPS Oct. 7 at 10:27 AM

0 · Reply

uptech Oct. 7 at 12:11 AM

2 · Reply

uptech Oct. 7 at 12:00 AM

$OMER OK Frog Soup is heating up. Last large buy tranche was at 3, but I did add more for kicks in low 4s. Rally hats on folks. Lets do this. Andiamo.

0 · Reply

HarveySpecter20 Oct. 6 at 9:16 PM

$OMER

0 · Reply

albert88 Oct. 6 at 7:08 PM

$OMER 5 coming.

0 · Reply

signaljumper Oct. 6 at 4:54 PM

$OMER time to load thiss biotech stock. Infos follow soon

1 · Reply

TheNewAxe Oct. 6 at 3:33 PM

$OMER Bought my last batch at 4.67, now back to 75k shares with a cost basis under 4 bucks in my taxable accounts.

3 · Reply

Phase3 Oct. 6 at 2:42 PM

$OMER yep, she's trying to break out...

1 · Reply

MikeLogan Oct. 6 at 2:29 PM

$OMER Looks like she wants higher. I was expecting a Monday morning selloff, not decent volume and green.

1 · Reply

robertward Oct. 6 at 12:27 AM

$OMER Got a good feeling about this week! Yep, I’m gonna keep saying this every single Sunday until something good happens 🤣🤣

3 · Reply

BorrowRate Oct. 5 at 3:37 PM

$OMER Biotech with clinical catalyst. High short interest. Volatility expansion expected. Pure binary event risk.

1 · Reply

LiquidThetaLEAPS Oct. 4 at 8:55 PM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $OMER Current Share Price: $4.58 Contracts: $OMER December 18, 2026 $5 Calls Scale in: $2.45- $3.00 Scale out: $3.81-$4.91 Can Easily Capture: 60% ROI Blended DTE: 441 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

Iceman89 Oct. 4 at 7:07 PM

$OMER The research around TM-TMA has accelerated in recent years, which is bullish for identifying all the patients to treat with Narsoplimab. "The MIDAS Consortium consists of 3 adult HCT centers, with a plan to enroll 1000 first allo HCT patients. Herein we report on the first 101 patients who have reached 1-year post-HCT" https://www.sciencedirect.com/science/article/pii/S2666636723017803?pes=vor&utm_source=wiley&getft_integrator=wiley

0 · Reply

vandy77 Oct. 4 at 10:05 AM

$OMER October could be a special month for us Seattleites. Seize the moment Omeros! https://x.com/mariners/status/1974318055783059955?s=46&t=BbibvRY7LLo3mUtZ9wBhQw

3 · Reply

SweepCastApp Oct. 4 at 8:04 AM

$OMER: Unusual Options Activity Alerted CALL flow observed 100x contracts at Strike price of $2 Exp on 10/17/2025 with Premium of $28K and showing BULLISH Sentiment

0 · Reply